Irradiated Allogeneic Cells
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New JerseyCell therapyEarly Phase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 73/ 100
Competitive context
108 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selinexor Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | BB |
DEXAMETHASONE City of Hope Medical Center | Phase 2/3 | BB |
Ifosfamide University of California, Davis | Phase 3 | BB |
ETOPOSIDE University of California, Davis | Phase 3 | BB |
Cyclophosphamide Nathan Denlinger | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Irradiated Allogeneic Cells is also rated in:
myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2Dormant
C
Indicative ·
39 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →